open access

Vol 16, No 1 (2020)
Review paper
Published online: 2020-01-17
Get Citation

Diagnosis and treatment of malignant PEComa tumours

Aleksandra Sobiborowicz, Anna M. Czarnecka, Anna Szumera-Ciećkiewicz, Piotr Rutkowski, Tomasz Świtaj
DOI: 10.5603/OCP.2020.0003
·
Oncol Clin Pract 2020;16(1):22-33.

open access

Vol 16, No 1 (2020)
REVIEW ARTICLES
Published online: 2020-01-17

Abstract

PEComa (PEC tumours; perivascular epithelioid cell tumours) is a family of rare tumours of mesenchymal origin, consisting of epithelial perivascular cells expressing melanocytic and myioid markers. This group includes benign tumours — such as angiomyolipoma (AML) of the kidney, and poorly differentiated malignant PEComa tumours with potential for an aggressive clinical course, which is the main focus of this review. PEComas are most often diagnosed in middle-aged women as extensive tumours located in the abdominal cavity or pelvis, manifesting as pain and complaints related to pressure on nearby organs. PEComa tumours should be differentiated from gastrointestinal stromal tumours (GIST), leiomyosarcoma, melanoma metastasis, chromophobic renal cell carcinoma, clear cel sarcoma, and other clear cell component tumours. Somatic inactivating mutations within the TSC1/TSC2 genes, resulting in excessive activation of the mTORC1 complex, are characteristic for this group of tumour. Recently, a separate PEComa subgroup has been distinguished, characterised by the presence of the TFE3 gene fusion, which also causes increased activity of the mTOR signalling pathway. Negative prognostic factors that indicate an increased risk of PEComa malignant biology are most often: tumour size > 5 cm, increased cytological and nuclear atypia, infiltration of surrounding tissues and blood vessels, presence of necrosis, and high mitotic activity. Radical resection remains the primary treatment method for PEComas because these tumours are characterised by high resistance to radiation and chemotherapy. In the case of locally advanced or metastatic disease, only single reports of short-term responses to palliative chemotherapy containing doxorubicin, gemcitabine, or ifosfamide are available in the literature. There are an increasing number of reports, in the form of several case reports and a few retrospective analyses, about the potential effectiveness of using mTOR inhibitors in unresectable cases. These drugs result in a reduction in primary tumour size and metastasis, as well as symptom relief, with controllable side effects. Unfortunately, case reports of complete resistance to mTOR inhibitor therapy are also available.

Abstract

PEComa (PEC tumours; perivascular epithelioid cell tumours) is a family of rare tumours of mesenchymal origin, consisting of epithelial perivascular cells expressing melanocytic and myioid markers. This group includes benign tumours — such as angiomyolipoma (AML) of the kidney, and poorly differentiated malignant PEComa tumours with potential for an aggressive clinical course, which is the main focus of this review. PEComas are most often diagnosed in middle-aged women as extensive tumours located in the abdominal cavity or pelvis, manifesting as pain and complaints related to pressure on nearby organs. PEComa tumours should be differentiated from gastrointestinal stromal tumours (GIST), leiomyosarcoma, melanoma metastasis, chromophobic renal cell carcinoma, clear cel sarcoma, and other clear cell component tumours. Somatic inactivating mutations within the TSC1/TSC2 genes, resulting in excessive activation of the mTORC1 complex, are characteristic for this group of tumour. Recently, a separate PEComa subgroup has been distinguished, characterised by the presence of the TFE3 gene fusion, which also causes increased activity of the mTOR signalling pathway. Negative prognostic factors that indicate an increased risk of PEComa malignant biology are most often: tumour size > 5 cm, increased cytological and nuclear atypia, infiltration of surrounding tissues and blood vessels, presence of necrosis, and high mitotic activity. Radical resection remains the primary treatment method for PEComas because these tumours are characterised by high resistance to radiation and chemotherapy. In the case of locally advanced or metastatic disease, only single reports of short-term responses to palliative chemotherapy containing doxorubicin, gemcitabine, or ifosfamide are available in the literature. There are an increasing number of reports, in the form of several case reports and a few retrospective analyses, about the potential effectiveness of using mTOR inhibitors in unresectable cases. These drugs result in a reduction in primary tumour size and metastasis, as well as symptom relief, with controllable side effects. Unfortunately, case reports of complete resistance to mTOR inhibitor therapy are also available.

Get Citation

Keywords

PEComa, perivascular epithelioid cell, mTOR

About this article
Title

Diagnosis and treatment of malignant PEComa tumours

Journal

Oncology in Clinical Practice

Issue

Vol 16, No 1 (2020)

Article type

Review paper

Pages

22-33

Published online

2020-01-17

DOI

10.5603/OCP.2020.0003

Bibliographic record

Oncol Clin Pract 2020;16(1):22-33.

Keywords

PEComa
perivascular epithelioid cell
mTOR

Authors

Aleksandra Sobiborowicz
Anna M. Czarnecka
Anna Szumera-Ciećkiewicz
Piotr Rutkowski
Tomasz Świtaj

References (100)
  1. Klimczak A, Pękul M, Wiater K, Rutkowski P. PEComa — grupa rzadkich nowotworów pochodzenia mezenchymalnego. 2011; 61(1): 52–56.
  2. Liegl B, Hornick JL, Fletcher CDM. Primary cutaneous PEComa: distinctive clear cell lesions of skin. Am J Surg Pathol. 2008; 32(4): 608–614.
  3. Bleeker JS, Quevedo JF, Folpe AL. Sarcoma. 2012; 2012: 541626.
  4. Armah HB, Parwani AV. Malignant perivascular epithelioid cell tumor (PEComa) of the uterus with late renal and pulmonary metastases: a case report with review of the literature. Diagn Pathol. 2007; 2: 45.
  5. Wagner AJ, Ravi V, Ganjoo KN, et al. ABI-009 (nab-sirolimus) in advanced malignant perivascular epithelioid cell tumors (PEComa): Preliminary efficacy, safety, and mutational status from AMPECT, an open label phase II registration trial. J Clin Oncol. 2019: 11005–11005.
  6. Sadigh S, Shah P, Weber K, et al. Primary malignant perivascular epithelioid cell neoplasm (PEComa) of the bone mimicking granular cell tumor in core biopsy: A case report and literature review. Oncol Lett. 2018; 15(3): 2946–2952.
  7. Agaram NP, Sung YS, Zhang L, et al. Dichotomy of Genetic Abnormalities in PEComas With Therapeutic Implications. Am J Surg Pathol. 2015; 39(6): 813–825.
  8. Chen Z, Han S, Wu J, et al. A systematic review: perivascular epithelioid cell tumor of gastrointestinal tract. Medicine (Baltimore). 2016; 95(28): e3890.
  9. Niu H, Wang FW, Zhang PJ, et al. Cardiac epithelioid PEComa: report of two cases and review of the literature. Case Rep Med. 2012; 2012: 521678.
  10. Nair AG, Gore SS, Ganvir AY, et al. Giant perivascular epithelioid cell tumor of the orbit: a clinicopathological analysis and review of the literature. Ocul Oncol Pathol. 2018; 4(5): 272–279.
  11. Doyle LA, Hornick JL, Fletcher CDM. PEComa of the gastrointestinal tract: clinicopathologic study of 35 cases with evaluation of prognostic parameters. Am J Surg Pathol. 2013; 37(12): 1769–1782.
  12. Zizzo M, Ugoletti L, Tumiati D, et al. Primary pancreatic perivascular epithelioid cell tumor (PEComa): A surgical enigma. A systematic review of the literature. Pancreatology. 2018; 18(3): 238–245.
  13. Sikora-Szczęśniak D. PEComa of the uterus — a case report. Ginekol Pol. 2013; 84(3): 234–236.
  14. D'Andrea D, Hanspeter E, D'Elia C, et al. Malignant perivascular epithelioid cell neoplasm (PEComa) of the Pelvis: a case report. Urol Case Rep. 2016; 6: 36–38.
  15. Lu B, Wang C, Zhang J, et al. Perivascular epithelioid cell tumor of gastrointestinal tract: case report and review of the literature. Medicine (Baltimore). 2015; 94(3): e393.
  16. Xu J, Yan Yu, Xiang X, et al. Gastric perivascular epithelioid cell tumor (PEComa). Am J Clin Pathol. 2019; 152(2): 221–229.
  17. Yanai H, Matsuura H, Sonobe H, et al. Perivascular epithelioid cell tumor of the jejunum. Pathol Res Pract. 2003; 199(1): 47–50.
  18. Ryan P, Nguyen VH, Gholoum S, et al. Polypoid PEComa in the rectum of a 15-year-old girl: case report and review of PEComa in the gastrointestinal tract. Am J Surg Pathol. 2009; 33(3): 475–482.
  19. Okamoto K, Okada Y, Ohno K, et al. A rare case of perivascular epithelioid cell tumor (PEComa) of the greater omentum. World J Surg Oncol. 2018; 16(1): 113.
  20. Zhao L, Anders KH. Malignant perivascular epithelioid cell tumor of the gallbladder: a case report and review of literature. Arch Pathol Lab Med. 2014; 138(9): 1238–1241.
  21. Sadeghi S, Krigman H, Maluf H. Perivascular epithelioid clear cell tumor of the common bile duct. Am J Surg Pathol. 2004; 28(8): 1107–1110.
  22. Kim H, Kim J, Lee SeK, et al. TFE3-Expressing perivascular epithelioid cell tumor of the breast. J Pathol Transl Med. 2019; 53(1): 62–65.
  23. Torii I, Kondo N, Takuwa T, et al. Perivascular epithelioid cell tumor of the rib. Virchows Arch. 2008; 452(6): 697–702.
  24. Lehman NL. Malignant PEComa of the skull base. Am J Surg Pathol. 2004; 28(9): 1230–1232.
  25. Tai Y, Wei L, Shi H. Perivascular epithelioid cell tumor of the heart in a child. Pediatr Dev Pathol. 2010; 13(5): 412–414.
  26. Mollazadeh R, Moaref A, Ghazinoor M, et al. Pericardial PEComa: echocardiographic features. International Journal of Cardiology. 2009; 132(1): e5–e7.
  27. Pan CC, Yang AH, Chiang H. Malignant perivascular epithelioid cell tumor involving the prostate. Arch Pathol Lab Med. 2003; 127(2): E96–98.
  28. Sbrollini G, Conti A, Galosi AB, et al. Perivascular epithelioid cell tumor (PEC-ome) of the prostate: ultrasound feature in case report. Arch Ital Urol Androl. 2014; 86(4): 393–394.
  29. Westaby JD, Magdy N, Fisher C, et al. Primary ovarian malignant PEComa: a case report. Int J Gynecol Pathol. 2017; 36(4): 400–404.
  30. Kuroda N, Goda M, Kazakov DV, et al. Perivascular epithelioid cell tumor of the nasal cavity with TFE3 expression. Pathol Int. 2009; 59(10): 769–770.
  31. Huai-yin S, Li-xin W, Lu S, et al. Perivascular epithelioid cell tumors of the laryngopharynx: three case reports and literature review. Pathol Res Pract. 2009; 205(9): 595–600.
  32. Palleschi G, Pastore AL, Evangelista S, et al. Bone metastases from bladder perivascular epithelioid cell tumor — an unusual localization of a rare tumor: a case report. J Med Case Rep. 2014; 8: 227.
  33. Chakrabarti A, Bandyopadhyay M, Purkayastha B. Malignant perivascular epitheloid cell tumour (PEComa) of the lung — a rare entity. Innov Surg Sci. 2017; 2(1): 39–42.
  34. Tynski Z, Chiang W, Barrett A. An inguinal perivascular epithelioid cell tumor metastatic to the orbit. Case Rep Pathol. 2018; 2018: 5749421.
  35. Zekry N, Rettenmaier MA, Abaid LN, et al. Perivascular epithelioid cell neoplasms: a systematic review of prognostic factors. J Minim Invasive Gynecol. 2009; 16(5): 527–532.
  36. Schoolmeester JK, Howitt BE, Hirsch MS, et al. Perivascular epithelioid cell neoplasm (PEComa) of the gynecologic tract: clinicopathologic and immunohistochemical characterization of 16 cases. Am J Surg Pathol. 2014; 38(2): 176–188.
  37. Okamoto S, Komura M, Terao Y, et al. Pneumothorax caused by cystic and nodular lung metastases from a malignant uterine perivascular epithelioid cell tumor (PEComa). Respir Med Case Rep. 2017; 22: 77–82.
  38. Parra-Medina R, Morales SD. Cutaneous perivascular epithelioid cell tumor of gynecologic origin metastatic to skin, lung, stomach, and brain. Am J Dermatopathol. 2017; 39(2): 157–159.
  39. Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29(Supplement_4): iv268–iv269.
  40. Tirumani SH, Shinagare AB, Hargreaves J, et al. Imaging features of primary and metastatic malignant perivascular epithelioid cell tumors. AJR Am J Roentgenol. 2014; 202(2): 252–258.
  41. Parfitt JR, Bella AJ, Izawa JI, Wehrli BM. Malignant neoplasm of perivascular epithelioid cells of the liver. Arch Pathol Lab Med. 2006; 130(8): 1219–1222.
  42. Maloney N, Giannikou K, Lefferts J, Bridge JA, Linos K. Expanding the Histomorphologic Spectrum of TFE3 Rearranged PEComas. Hum Pathol. 2018.
  43. Iwa N, Yutani C, Kobayashi TK. Presence of eosinophilic intracytoplasmic inclusions diagnosed by fine needle aspiration cytology in perivascular epithelioid cell tumor (PEComa) arising from the cecum. Diagn Cytopathol. 2019; 47(4): 359–361.
  44. Folpe AL, Mentzel T, Lehr HA, et al. Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin: a clinicopathologic study of 26 cases and review of the literature. Am J Surg Pathol. 2005; 29(12): 1558–1575.
  45. Bennett JA, Braga AC, Pinto A, et al. Uterine PEComas: a morphologic, immunohistochemical, and molecular analysis of 32 tumors. Am J Surg Pathol. 2018; 42(10): 1370–1383.
  46. Hornick JL, Fletcher CDM. Sclerosing PEComa: clinicopathologic analysis of a distinctive variant with a predilection for the retroperitoneum. Am J Surg Pathol. 2008; 32(4): 493–501.
  47. Martignoni G, Bonetti F, Chilosi M, et al. Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. Mod Pathol. 2012; 25(1): 100–111.
  48. Gulavita P, Fletcher CDM, Hirsch MS. PNL2: an adjunctive biomarker for renal angiomyolipomas and perivascular epithelioid cell tumours. Histopathology. 2018; 72(3): 441–448.
  49. Abhirup B, Kaushal K, Sanket M, et al. Malignant hepatic perivascular epithelioid cell tumor (PEComa) — case report and a brief review. J Egypt Natl Canc Inst. 2015; 27(4): 239–242.
  50. Fernandez-Flores A, Nguyen CM, Cassarino DS. Cutaneous PEComas Express CD10: Implications for the Classification of PEComas and the Differential Diagnosis With Metastatic Renal Cell Carcinoma. Am J Dermatopathol. 2016; 38(9): 645–652.
  51. Armah HB, Parwani AV. Perivascular epithelioid cell tumor. Arch Pathol Lab Med. 2009; 133(4): 648–654.
  52. Sangiorgio V, Daniele L, Gallo T, et al. Ultrasound-guided fine needle aspiration cytology in the diagnosis of hepatic and pancreatic perivascular epithelioid cell tumors: A case series. Diagn Cytopathol. 2019; 47(4): 315–319.
  53. Pan CC, Jong YJ, Chai CY, et al. Comparative genomic hybridization study of perivascular epithelioid cell tumor: molecular genetic evidence of perivascular epithelioid cell tumor as a distinctive neoplasm. Hum Pathol. 2006; 37(5): 606–612.
  54. Pan CC, Chung MY, Ng KF, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol. 2008; 214(3): 387–393.
  55. Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol. 2007; 38(9): 1361–1371.
  56. Sukov WR, Hodge JC, Lohse CM, et al. TFE3 rearrangements in adult renal cell carcinoma: clinical and pathologic features with outcome in a large series of consecutively treated patients. Am J Surg Pathol. 2012; 36(5): 663–670.
  57. Jaber OI, Kirby PA. Alveolar soft part sarcoma. Arch Pathol Lab Med. 2015; 139(11): 1459–1462.
  58. Hua X, Liu X, Ansari DO, et al. Synergistic cooperation of TFE3 and smad proteins in TGF-beta-induced transcription of the plasminogen activator inhibitor-1 gene. Genes Dev. 1998; 12(19): 3084–3095.
  59. Jones E, Inoki K. Microphthalmia-associated transcription factors activate mTORC1 through RagD GTPase gene expression. Transl Cancer Res. 2017; 6(Suppl 7): S1234–S1238.
  60. Slade L, Pulinilkunnil T. The MiTF/TFE family of transcription factors: master regulators of organelle signaling, metabolism, and stress adaptation. Mol Cancer Res. 2017; 15(12): 1637–1643.
  61. Rao Q, Shen Q, Xia Qy, et al. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity. Am J Surg Pathol. 2015; 39(9): 1181–1196.
  62. Argani P, Aulmann S, Illei PB, et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am J Surg Pathol. 2010; 34(10): 1395–1406.
  63. Alnajar H, Brickman A, Buckingham L, et al. Metastatic malignant PEComa of the leg with identification of ATRX mutation by next-generation sequencing. Virchows Arch. 2018; 472(3): 499–503.
  64. Koelsche C, Renner M, Johann P, et al. Differential nuclear ATRX expression in sarcomas. Histopathology. 2016; 68(5): 738–745.
  65. Liau JY, Tsai JH, Jeng YM, et al. Leiomyosarcoma with alternative lengthening of telomeres is associated with aggressive histologic features, loss of ATRX expression, and poor clinical outcome. Am J Surg Pathol. 2015; 39(2): 236–244.
  66. Rutkowski PL, Mullen JT. Management of the "Other" retroperitoneal sarcomas. J Surg Oncol. 2018; 117(1): 79–86.
  67. Machado I, Cruz J, Lavernia J, et al. Malignant PEComa with metastatic disease at diagnosis and resistance to several chemotherapy regimens and targeted therapy (m-TOR inhibitor). Int J Surg Pathol. 2017; 25(6): 543–549.
  68. Kirste S, Kayser G, Zipfel A, et al. Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection. Radiat Oncol. 2018; 13(1): 28.
  69. Liu JL, Lin YM, Lin MC, et al. Perivascular epithelioid cell tumor (PEComa) of the uterus with aggressive behavior at presentation. Hematol Oncol Stem Cell Ther. 2009; 2(3): 426–430.
  70. Sanfilippo R, Jones RL, Blay J-Y, et al. Role of chemotherapy, VEGFR inhibitors and mTOR Inhibitors in advanced Perivascular Epithelioid Cell Tumours (PEComas)." Clinical Cancer Research: clincanres.0288.2019.
  71. Osei DA, Alvandi F, Brooks JS, et al. PEComa of the upper extremity: a unique case and description of an initial response to neoadjuvant chemotherapy. Sarcoma. 2007; 2007: 53056.
  72. Scheppach W, Reissmann N, Sprinz T, et al. PEComa of the colon resistant to sirolimus but responsive to doxorubicin/ifosfamide. World J Gastroenterol. 2013; 19(10): 1657–1660.
  73. Rutkowski P, Przybył J, Świtaj T. Genetics of rare mesenchymal tumors: implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa. Int J Biochem Cell Biol. 2014; 53: 466–474.
  74. Benson C, Vitfell-Rasmussen J, Maruzzo M, et al. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience. Anticancer Res. 2014; 34(7): 3663–3668.
  75. Raimondi A, Colombo F, Pintarelli G, et al. Prolonged activity and toxicity of sirolimus in a patient with metastatic renal perivascular epithelioid cell tumor: a case report and literature review. Anticancer Drugs. 2018; 29(6): 589–595.
  76. Gondran H, Thebaud E, Moreau A, et al. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor. Pancreatology 2019.
  77. Huľová S, Sycova-Mila Z, Macák D, et al. Diagnostic challenges and extraordinary treatment response in rare malignant PEComa tumor of the kidney. Klin Onkol. 2018; 31(6): 448–452.
  78. Italiano A, Delcambre C, Hostein I, et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010; 21(5): 1135–1137.
  79. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol. 2010; 28(5): 835–840.
  80. Gennatas C, Michalaki V, Kairi PV, et al. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor. World J Surg Oncol. 2012; 10: 181.
  81. Dickson MA, Schwartz GK, Antonescu CR, et al. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates. Int J Cancer. 2013; 132(7): 1711–1717.
  82. Bergamo F, Maruzzo M, Basso U, et al. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa). World J Surg Oncol. 2014; 12: 46.
  83. Nakanishi S, Miyazato M, Yonemori K, et al. Perirenal malignant perivascular epithelioid cell tumor originating from right retroperitoneum: a case report. Hinyokika Kiyo. 2014; 60(12): 627–630.
  84. Bunch K, Sunde J. Fertility sparing treatment of a malignant uterine perivascular epithelioid cell tumor: A case report. Gynecol Oncol Case Rep. 2014; 8: 14–16.
  85. Ghosh I, Arun I, Sen S, et al. Metastatic perivascular epithelioid cell tumor responding to mammalian target of rapamycin inhibition. Indian J Med Paediatr Oncol. 2014; 35(1): 99–102.
  86. Chen S-C, Yang C-W, Yen C-C, Tseng C-H, Chao T-C. Perivascular epithelioid cell tumors (PEComas) refractory to mTOR inhibitors. Journal of Cancer Research and Practice. 2014; 1(2): 128–133.
  87. Weeber F, Koudijs MJ, Hoogstraat M, et al. Effective therapeutic intervention and comprehensive genetic analysis of mTOR signaling in PEComa: A Case Report. Anticancer Res. 2015; 35(6): 3399–3403.
  88. Sun Lu, Sun X, Li Y, et al. The role of (18)F-FDG PET/CT imaging in patient with malignant PEComa treated with mTOR inhibitor. Onco Targets Ther. 2015; 8: 1967–1970.
  89. Gao F, Huang C, Zhang Y, et al. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa. Cancer Biol Ther. 2016; 17(6): 595–598.
  90. Liu TH, Liang CW, Lu LC. Perivascular epithelioid cell tumor of the gastrointestinal tract. Journal of Cancer Research and Practice. 2016; 3(1): 14–18.
  91. Binyamin K, Mecz Y, Stein A, et al. An Aggressive Case of Malignant Renal Pecoma Non-Responsive to Motor Inhibition: A Case Report. Journal of Clinical Case Reports. 2016; 6(10).
  92. Starbuck KD, Drake RD, Budd GT, et al. Treatment of advanced malignant uterine perivascular epithelioid cell tumor with mTOR inhibitors: single-institution experience and review of the literature. Anticancer Res. 2016; 36(11): 6161–6164.
  93. Flechter E, Zohar Y, Guralnik L, et al. Long-lasting stable disease with mTOR inhibitor treatment in a patient with a perivascular epithelioid cell tumor: A case report and literature review. Oncol Lett. 2016; 12(6): 4739–4743.
  94. Batereau C, Knösel T, Angele M, et al. Neoadjuvant or adjuvant sirolimus for malignant metastatic or locally advanced perivascular epithelioid cell tumors. Anti-Cancer Drugs. 2016; 27(3): 254–258.
  95. Shaikh AJ. Malignant Pervascular Epitheloid Cell Tumor (PEComa), Presenting as a Large Intra-Abdominal Mass in a Young Woman: A Case Report and Review of Literature. Journal of Cancer Prevention & Current Research. 2016; 4(6).
  96. Rao S, Pavithra P, Bhat S, et al. Cardiac perivascular epithelioid cell tumor. World J Pediatr Congenit Heart Surg. 2017 [Epub ahead of print]: 2150135116682452.
  97. Varan A, Bayhan T, Kiratli H, et al. An orbital perivascular epithelioid cell tumor in a 7-year-old boy: case report and review of the literature. J AAPOS. 2017; 21(4): 325–328.e1.
  98. Tang SH, Liu YC, Hsiao HH, et al. Huge soft tissue PEComa with aggressive lung and bone metastases. Journal of Cancer Research and Practice. 2017; 4(3): 115–118.
  99. Kwon BSu, Suh DS, Lee NK, et al. Two cases of perivascular epithelioid cell tumor of the uterus: clinical, radiological and pathological diagnostic challenge. Eur J Med Res. 2017; 22(1): 7.
  100. Saluja K, Thomas J, Zhang S, et al. Malignant perivascular epithelioid cell tumor of the oropharynx with strong TFE3 expression mimicking alveolar soft part sarcoma: a case report and review of the literature. Hum Pathol. 2018; 76: 149–155.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl